2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by REMUZZI, G. Articles by BENIGNI, A. Search for Related Content PubMed PubMed Citation Articles by REMUZZI, G. Articles by BENIGNI, A.

Combining an Antiproteinuric Approach with Mycophenolate Mofetil Fully Suppresses Progressive Nephropathy of Experimental Animals

GIUSEPPE REMUZZI^*,, CARLA ZOJA^*, ELENA GAGLIARDINI^*, DANIELA CORNA^*, MAURO ABBATE^* and ARIELA BENIGNI^*

^* Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy.

Correspondence to Dr. Mauro Abbate, "Mario Negri" Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. Phone: +39 035 319 888; Fax: +39 035 319 331; E-mail: abbate{at}irfmn.mnegri.it

Abstract. Chronic renal diseases progress to organ insufficiency, which may require replacement therapy within one to three decades even independently of the type of initial insults. In the majority of cases, the degrees of proteinuria and interstitial leukocyte infiltration and scarring are strictly correlated with the rate of disease progression. This study tests the hypothesis that excess intrarenal protein traffic may cause lymphocyte-dependent interstitial injury that, while not fully controlled by antiproteinuric therapy, can be further inhibited by concomitant immunosuppression. A primarily nonimmune model was used to reproduce progressive renal disease due to a critical loss of nephron mass. Angiotensin-converting enzyme (ACE) inhibitor limited proteinuria, interstitial inflammation, MHC class II antigen expression, and severe lesions. Combined treatment with ACE inhibitor and a specific antilymphocyte agent, mycophenolate mofetil, dramatically attenuated macrophage and T cell infiltration, MHC-class II over-expression, dendritic cells, and all manifestations of the disease. Evidence of lymphocyte-mediated renal injury in the setting of excess protein traffic provides the basis for combining ACE inhibition and immunosuppression to halt progression of proteinuric kidney disease and minimize the need for dialysis or transplantation.

This article has been cited by other articles:

				D. Macconi, C. Chiabrando, S. Schiarea, S. Aiello, L. Cassis, E. Gagliardini, M. Noris, S. Buelli, C. Zoja, D. Corna, et al. Proteasomal Processing of Albumin by Renal Dendritic Cells Generates Antigenic Peptides J. Am. Soc. Nephrol., January 1, 2009; 20(1): 123 - 130. [Abstract] [Full Text] [PDF]

				V Teplitsky, Y Shoenfeld, and A Tanay The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans Lupus, June 1, 2006; 15(6): 319 - 325. [Abstract] [PDF]

				F. Nakhoul, R. Ramadan, E. Khankin, A. Yaccob, Z. Kositch, M. Lewin, S. Assady, and Z. Abassi Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies Am J Physiol Renal Physiol, October 1, 2005; 289(4): F880 - F890. [Abstract] [Full Text] [PDF]

				S. Kramer, T. Loof, S. Martini, M. Ruckert, Y. Wang, T. Bohler, F. Shimizu, H. Kawachi, H.-H. Neumayer, and H. Peters Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril Am J Physiol Renal Physiol, August 1, 2005; 289(2): F359 - F368. [Abstract] [Full Text] [PDF]

				J. F. Navarro, C. Mora, M. Muros, and J. Garcia Additive Antiproteinuric Effect of Pentoxifylline in Patients with Type 2 Diabetes under Angiotensin II Receptor Blockade: A Short-Term, Randomized, Controlled Trial J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2119 - 2126. [Abstract] [Full Text] [PDF]

				E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]

				A. R. R. Goncalves, C. K. Fujihara, A. L. Mattar, D. M. A. C. Malheiros, I. L. Noronha, G. de Nucci, and R. Zatz Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory Am J Physiol Renal Physiol, May 1, 2004; 286(5): F945 - F954. [Abstract] [Full Text] [PDF]

				B. Rodriguez-Iturbe, N. D. Vaziri, J. Herrera-Acosta, and R. J. Johnson Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all Am J Physiol Renal Physiol, April 1, 2004; 286(4): F606 - F616. [Abstract] [Full Text] [PDF]

				M. Abbate and G. Remuzzi Can We Really Lessen Kidney Damage to the Point that the Loss of Renal Function of Progressive Nephropathy May Revert? J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1411 - 1414. [Full Text] [PDF]

				G. D Laverman, D. de Zeeuw, and G. Navis Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 205 - 213. [Abstract] [PDF]

				S.-L. Lin, Y.-M. Chen, C.-T. Chien, W.-C. Chiang, C.-C. Tsai, and T.-J. Tsai Pentoxifylline Attenuated the Renal Disease Progression in Rats with Remnant Kidney J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2916 - 2929. [Abstract] [Full Text] [PDF]

				R. Zatz, I. L. Noronha, and C. K. Fujihara Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies Am J Physiol Renal Physiol, December 1, 2002; 283(6): F1167 - F1175. [Abstract] [Full Text] [PDF]

				M. Abbate, C. Zoja, M. Morigi, D. Rottoli, S. Angioletti, S. Tomasoni, C. Zanchi, L. Longaretti, R. Donadelli, and G. Remuzzi Transforming Growth Factor-{beta}1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins: A Central Pathway in Progressive Glomerulosclerosis Am. J. Pathol., December 1, 2002; 161(6): 2179 - 2193. [Abstract] [Full Text] [PDF]

				V. Alvarez, Y. Quiroz, M. Nava, H. Pons, and B. Rodriguez-Iturbe Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells Am J Physiol Renal Physiol, November 1, 2002; 283(5): F1132 - F1141. [Abstract] [Full Text] [PDF]

				D. F. Sun, Y. Fujigaki, T. Fujimoto, T. Goto, K. Yonemura, and A. Hishida Mycophenolate Mofetil Inhibits Regenerative Repair in Uranyl Acetate-Induced Acute Renal Failure by Reduced Interstitial Cellular Response Am. J. Pathol., July 1, 2002; 161(1): 217 - 227. [Abstract] [Full Text] [PDF]

				I. L. Noronha, C. K. Fujihara, and R. Zatz The inflammatory component in progressive renal disease--are interventions possible? Nephrol. Dial. Transplant., March 1, 2002; 17(3): 363 - 368. [Full Text] [PDF]

				C. Badid, A. Desmouliere, and M. Laville Mycophenolate mofetil: implications for the treatment of glomerular disease Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1752 - 1756. [Full Text] [PDF]

				Y. Quiroz, H. Pons, K. L. Gordon, J. Rincon, M. Chavez, G. Parra, J. Herrera-Acosta, D. Gomez-Garre, R. Largo, J. Egido, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition Am J Physiol Renal Physiol, July 1, 2001; 281(1): F38 - F47. [Abstract] [Full Text] [PDF]

				D. Gomez-Garre, R. Largo, N. Tejera, J. Fortes, F. Manzarbeitia, and J. Egido Activation of NF-{{kappa}}B in Tubular Epithelial Cells of Rats With Intense Proteinuria : Role of Angiotensin II and Endothelin-1 Hypertension, April 1, 2001; 37(4): 1171 - 1178. [Abstract] [Full Text] [PDF]

				C. K. Fujihara, D. M. Avancini Costa Malheiros, I. de Lourdes Noronha, G. De Nucci, and R. Zatz Mycophenolate Mofetil Reduces Renal Injury in the Chronic Nitric Oxide Synthase Inhibition Model Hypertension, January 1, 2001; 37(1): 170 - 175. [Abstract] [Full Text] [PDF]

				B. Rodriguez-Iturbe, Y. Quiroz, M. Nava, L. Bonet, M. Chavez, J. Herrera-Acosta, R. J. Johnson, and H. A. Pons Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats Am J Physiol Renal Physiol, February 1, 2002; 282(2): F191 - F201. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673